Alligator Bioscience AB

ATORX

SE0000767188

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 12:51:34 30/05/2024 BST			5-day change	1st Jan Change
0.995 ^SEK	+3.54%		+8.82%	+41.51%

05-23	Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	CI
05-21	US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	MT

Alligator Bioscience AB Elects Board of Directors

May 05, 2022 at 10:30 am

Alligator Bioscience AB (publ) announced annual general meeting held on May 5, 2022, the shareholders elected Staffan Encrantz and Denise Goode as new board members of the company.

Latest news about Alligator Bioscience AB

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	05-23	CI
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	05-21	MT
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	05-14	CI
Transcript : Alligator Bioscience AB, Q1 2024 Earnings Call, May 06, 2024	05-06
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	04-26	CI
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	04-05	CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	03-26	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	03-07	CI
Transcript : Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024	02-09
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan	02-09	MT
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan	02-09	MT
Alligator Bioscience to Trim Workforce Amid Restructuring Program	02-08	MT
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-08	CI
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce	02-08	CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation	02-08	CI
Transcript : Alligator Bioscience AB - Special Call	01-29
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	01-29	CI
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody	01-16	MT
Transcript : Alligator Bioscience AB - Analyst/Investor Day	12-01
Certain Ordinary Shares of Alligator Bioscience AB are subject to a Lock-Up Agreement Ending on 9-NOV-2023.	11-08	CI
Alligator Bioscience AB Appoints Bertil Brinck as Chairman of the Nomination Committee	11-06	CI
Transcript : Alligator Bioscience AB, Q3 2023 Earnings Call, Oct 26, 2023	26/10/23
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab	12/10/23	CI

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Meeting - Abstract No 2569

More about the company

Income Statement Evolution

More financial data

Ratings for Alligator Bioscience AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.961 SEK

Average target price

1.9 SEK

Spread / Average Target

+97.71%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALLIGATOR BIOSCIENCE AB	+41.51%	68.38M
MODERNA, INC.	+48.67%	56.69B
IQVIA HOLDINGS INC.	-2.76%	41B
LONZA GROUP AG	+37.94%	38.11B
CELLTRION, INC.	-11.22%	26.89B
ICON PUBLIC LIMITED COMPANY	+9.25%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-23.10%	18.59B
BIO-TECHNE CORPORATION	+1.88%	12.39B
MEDPACE HOLDINGS, INC.	+26.43%	11.99B
UNITED THERAPEUTICS CORPORATION	+21.74%	11.88B

Other Biotechnology & Medical Research